BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics

UnknownOBSERVATIONAL
Enrollment

130

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

September 30, 2020

Study Completion Date

March 31, 2021

Conditions
Non Small Cell Lung CancerMicrobiomeMetagenomeImmunotherapyMelanoma
Interventions
BIOLOGICAL

Collection of stool, blood (PBMC) and biopsy (FFPE)

Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).

Trial Locations (10)

Unknown

RECRUITING

University Clinical Centre in Gdansk, Gdansk

RECRUITING

The John Paul II Hospital in Krakow, Krakow

NOT_YET_RECRUITING

The Maria Sklodowska-Curie National Research Institute of Oncology Krakow Branch, Krakow

WITHDRAWN

Poznań University Hospital of Lord's Transfiguration, Poznan

RECRUITING

Provincial Hospital St. Father Pio in Przemyśl, Przemyśl

RECRUITING

"Mountains Center of Pulmonology and Chemotherapy Izer-Med", Szklarska Poręba

RECRUITING

Specialist Oncological Hospital, Tomaszów Mazowiecki

RECRUITING

The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Warsaw

RECRUITING

Masovian Oncology Hospital in Wieliszew, Wieliszew

WITHDRAWN

Lower Silesian Oncology Center & Łukasiewicz Research Network - PORT Polish Center For Technology Development, Wroclaw

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Center for Research and Development, Poland

OTHER

lead

Ardigen

INDUSTRY

NCT04136470 - BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics | Biotech Hunter | Biotech Hunter